Materials and methods for assay of anti-hepatitis C virus (HCV) antibodies

• US 9,551,714 B2
• Filed: 06/24/2011
• Issued: 01/24/2017
• Est. Priority Date: 06/25/2010
• Status: Active Grant

• Current Assignee: Abbott Laboratories Incorporated
• Original Assignee: Abbott Laboratories Incorporated
• Inventors: Leary, Thomas P., Gutierrez, Robin A., Muerhoff, A. Scott, Dawson, George J., Desai, Suresh M., Shah, Dinesh
• Primary Examiner(s): Zou, Nick
• Application Number:
  US13/168,373
• Publication Number:
  US 20120202295A1
• Time in Patent Office: 2,041 Days
• Field of Search: None
• US Class Current: 1/1
• CPC Class Codes: C07K 14/005 from viruses
• CPC Class Codes: C12N 2770/24222 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
• CPC Class Codes: G01N 2333/186 Hepatitis C; Hepatitis NANB
• CPC Class Codes: G01N 2469/20 Detection of antibodies in sample from host which are directed against antigens from microorganisms
• CPC Class Codes: G01N 33/5767 non-A, non-B hepatitis

Abstract

A polypeptide comprising the contiguous amino acids 1-198 of SEQ ID NO: 2; a polypeptide, which comprises a contiguous amino acid sequence that is at least about 95% identical to the contiguous amino acids 1-198 of SEQ ID NO: 2, an epitope that is immunoreactive with an antibody that specifically binds to the core protein of hepatitis C virus (HCV), and an epitope that is immunoreactive with an antibody that specifically binds to the NS4 region of HCV; a nucleic acid encoding such a polypeptide; a host cell comprising such a nucleic acid; an immunodiagnostic reagent comprising such a polypeptide; a kit comprising such an immunodiagnostic reagent; and a method of determining the presence, amount, or concentration of anti-HCV antibodies in a test sample.

Claims

1. An immunodiagnostic reagent consisting essentially of

(a) an isolated or purified polypeptide consisting essentially of the contiguous amino acids 1-198 of SEQ ID NO:

2 or a contiguous amino acid sequence that is at least 95% identical to the contiguous amino acids 1-198 of SEQ ID NO;

2 and

(b) an isolated or purified polypeptide consisting essentially of (i) an epitope that is immunoreactive with an antibody that specifically binds to the NS3 region of HCV and (ii) an epitope that is immunoreactive with an antibody that specifically binds to the core region of HCV, wherein the isolated or purified polypeptide consists essentially of the contiguous amino acids 2-267 and 270-419 of SEQ ID NO;

4,

wherein (a) and (b) are co-coated on the same microparticles in a ratio of about 1;

2 and concentration of (a) is at least about 40 μ

g/mL and the concentration of (b) is at least about 80 μ

g/mL.

2. A kit consisting of the immunodiagnostic reagent of claim 1 and instructions for the use of the immunodiagnostic reagent in the immunoassay of anti-HCV antibodies.

3. A method of determining the presence, amount, or concentration of anti-HCV antibodies in a test sample, which method comprises assaying the test sample for anti-HCV antibodies by an assay:

(i) employing;

(i′

) an immunodiagnostic reagent comprising at least one pair of first specific binding partners selected from the group consisting of

(1) an isolated or purified polypeptide consisting essentially of the contiguous amino acids 1-198 of SEQ ID NO;

2 or a contiguous amino acid sequence that is at least 95% identical to the contiguous amino acids 1-198 of SEQ ID NO;

2 and an isolated or purified polypeptide comprising an epitope that is immunoreactive with an antibody that specifically binds to the NS3 region of HCV,

(2) an isolated or purified polypeptide consisting essentially of the contiguous amino acids 1-198 of SEQ ID NO;

2 or a contiguous amino acid sequence that is at least 95% identical to the contiguous amino acids 1-198 of SEQ ID NO;

2 and an isolated or purified polypeptide comprising the contiguous amino acids 2-267 of SEQ ID NO;

4,

(3) an isolated or purified polypeptide consisting essentially of the contiguous amino acids 1-198 of SEQ ID NO;

2 or a contiguous amino acid sequence that is at least 95% identical to the contiguous amino acids 1-198 of SEQ ID NO;

2 and an isolated or purified polypeptide comprising an epitope that is immunoreactive with an antibody that specifically binds to the NS3 region of HCV and an epitope that is immunoreactive with an antibody that specifically binds to the core region of HCV, and

(4) an isolated or purified polypeptide consisting essentially of the contiguous amino acids 1-198 of SEQ ID NO;

2 or a contiguous amino acid sequence that is at least 95% identical to the contiguous amino acids 1-198 of SEQ ID NO;

2 and an isolated or purified polypeptide comprising the contiguous amino acids 2-267 and 270-419 of SEQ ID NO;

4, and

(ii′

) at least one detectable label, and

(ii) comprising;

comparing a signal generated by the detectable label as a direct or indirect indication of the presence, amount or concentration of anti-HCV antibodies in the test sample to a signal generated as a direct or indirect indication of the presence, amount or concentration of anti-HCV antibodies in a control or calibrator, which is optionally part of a series of calibrators in which each of the calibrators differs from the other calibrators in the series by the concentration of anti-HCV antibodies, whereupon the presence, amount or concentration of anti-HCV antibodies in the test sample is determined,

wherein the polypeptides of which the immunodiagnostic reagent is comprised are co-coated on the same microparticles in a ratio of about 1;

2 and the concentration of the isolated or purified polypeptide consisting essentially of the contiguous amino acids 1-198 of SEQ ID NO;

2 or a contiguous amino acid sequence that is at least about 95% identical to the contiguous amino acids 1-198 of SEQ ID NO;

2 is at least about 40 μ

g/mL and the concentration of the other isolated or purified polypeptide is at least about 80 μ

g/mL.

4. The method of claim 3, which comprises the following steps:

(i) contacting the test sample with the immunodiagnostic reagent so as to form first specific binding partner/anti-HCV antibody complexes,

(ii) contacting the first specific binding partner/anti-HCV antibody complexes with at least one detectably labeled second specific binding partner for anti-HCV antibody so as to form first specific binding partner/anti-HCV antibody/second specific binding partner complexes, and

(iii) determining the presence, amount or concentration of anti-HCV antibodies in the test sample by detecting or measuring the signal generated by the detectable label in the first specific binding partner/anti-HCV antibody/second specific binding partner complexes formed in (ii),

whereupon the presence, amount or concentration of anti-HCV antibodies in the test sample is determined.

5. The method of claim 3, which comprises the following steps:

(i) contacting the test sample with the immunodiagnostic reagent and simultaneously or sequentially, in either order, contacting the test sample with at least one detectably labeled second specific binding partner, which can compete with anti-HCV antibody for binding to the at least one pair of first specific binding partners and which comprises detectably labeled anti-HCV antibodies, wherein any anti-HCV antibody present in the test sample and the at least one detectably labeled second specific binding partner compete with each other to form first specific binding partner/anti-HCV antibody complexes and a first specific binding partner/second specific binding partner complexes, respectively, and

(ii) determining the presence, amount or concentration of anti-HCV antibodies in the test sample by detecting or measuring the signal generated by the detectable label in the first specific binding partner/second specific binding partner complex formed in (ii), wherein the signal generated by the detectable label in the first specific binding partner/second specific binding partner complex is inversely proportional to the amount or concentration of anti-HCV antibodies in the test sample,

whereupon the presence, amount or concentration of anti-HCV antibodies in the test sample is determined.

6. The method of claim 3, wherein the test sample was obtained from a patient and the method further comprises diagnosing, prognosticating, or assessing the efficacy of a therapeutic/prophylactic treatment of the patient, wherein, if the method further comprises assessing the efficacy of a therapeutic/prophylactic treatment of the patient, the method optionally further comprises modifying the therapeutic/prophylactic treatment of the patient as needed to improve efficacy.

7. The method of claim 3, wherein the method is adapted for use in an automated system or a semi-automated system.